Skip to content
value.today

Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc. is listed today as Whitehawk Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Aerpio Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$100 MPrivate placement after listing$50 to $250 million

Aerpio Pharmaceuticals, Inc.: Private sale, Mar 2025

Investors in this round

17 investors had bought by the notice of Mar 18, 2025: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,335,553
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Ball · Executive Officer
  • Dave Lennon · Executive Officer, Director
  • David Dornan · Executive Officer
  • Scott Giacobello · Executive Officer
  • Anupam Dalal · Director
  • Baiteng Zhao · Director
  • Behzad Aghazadeh · Director
  • Caley Castelein · Director
  • Emma Reeve · Director
  • Karin Hehenberger · Director
  • Mohammad Hirmand · Director
  • Neil Desai · Director
  • Richard Maroun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Jefferies, LLC acting as placement agent.”

Signed by Steve Rodin, SVP and General Counsel. Newest notice filed Mar 18, 2025. Read the notice at the SEC.

equity, optionsSEC
Sep 2022$73 MPrivate placement after listing$50 to $250 million

Aerpio Pharmaceuticals, Inc.: Private sale, Sep 2022

Investors in this round

13 investors had bought by the notice of Oct 11, 2022: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$73 M of $73 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brendan Delaney · Executive Officer
  • Loretta Itri · Executive Officer
  • Neil Desai · Executive Officer, Director
  • Scott Giacobello · Executive Officer
  • Anupam Dalal · Director
  • Behzad Aghazadeh · Director
  • Caley Castelein · Director
  • Emma Reeve · Director
  • Karin Hehenberger · Director
  • Richard Maroun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Scott Giacobello, Chief Financial Officer. Newest notice filed Oct 11, 2022. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$155 MPrivate placement after listing$50 to $250 million

Aerpio Pharmaceuticals, Inc.: Private sale, Aug 2021

Investors in this round

31 investors had bought by the notice of Sep 10, 2021: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$155 M of $155 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$9,345,479
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lance Thibault · Executive Officer
  • Neil Desai · Executive Officer, Director
  • Anupam Dalal · Director
  • Caley Castelein · Director
  • Emma Reeve · Director
  • Karin Heneberger · Director
  • Richard Maroun · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company LLC (CRD 7616) · broker-dealer Cowen and Company LLC (CRD 7616) · New York, New YorkSold in CA, MD, NY, PA, TN
  • Jefferies LLC (CRD 2347) · broker-dealer Jefferies LLC (CRD 2347) · New York, New YorkSold in CA, MD, NY, PA, TN
  • Piper Sandler & Co. (CRD 665) · broker-dealer Piper Sandler & Co. (CRD 665) · New York, New YorkSold in CA, MD, NY, PA, TN

Signed by Lance Thibault, Chief Financial Officer. Newest notice filed Sep 10, 2021 (1 amendment). Read the notice at the SEC.

equitySEC
Mar 2017$42 MPrivate placement after listing$10 to $50 million

Aerpio Pharmaceuticals, Inc.: Private sale, Mar 2017

Investors in this round

264 investors had bought by the notice of Mar 30, 2017: 264 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,229,507
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James M. Murphy · Executive Officer
  • Joseph Gardner · Executive Officer, Director
  • Kevin G. Peters · Executive Officer
  • Stephen G. Pakola · Executive Officer
  • Anupam M. Dalal · Director
  • Caley M. Castelein · Director
  • Chau M. Khuong · Director
  • Muneer Satter · Director
  • Paul M. Weiss · Director
  • Pravin M. Dugel · Director
  • Steven M. Prelack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Katalyst Securities LLC (CRD 112494) · Astoria, New YorkSold in AK, AL, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, ND, NH, NJ, NV, NY, OH, OK, OR, PA, RI, SC, TX, UT, VA, VT, WA, WI, WV
  • National Securities Corporation (CRD 7569) · Seattle, WashingtonSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY
  • Raymond James & Associates, Inc. (CRD 705) · St. Petersburg, FloridaSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Remarks in the notice

  • On fees: “A portion of the sales commissions paid included warrants to purchase common stock.”
  • On the amounts: “A portion of the overall offering amount was comprised of warrants to purchase common stock of Aerpio Pharmaceuticals, Inc.”

Signed by Joseph H. Gardner, President & CEO. Newest notice filed Mar 30, 2017. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Whitehawk Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $7.14 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Aerpio Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2025).

    SEC Form D · Mar 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2025

Products and services#

No products or services of Aerpio Pharmaceuticals, Inc. are on record.

Investors#

No investor of Aerpio Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Whitehawk Therapeutics, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aerpio Pharmaceuticals, Inc.
NameRoleNamed in
Bryan BallExecutive officerMar 2025
Dave LennonExecutive officerMar 2025
David DornanExecutive officerMar 2025
Scott GiacobelloExecutive officerMar 2025
Brendan DelaneyExecutive officerOct 2022
Loretta ItriExecutive officerOct 2022
Neil DesaiExecutive officerOct 2022
Lance ThibaultExecutive officerSep 2021
James M. MurphyExecutive officerMar 2017
Joseph GardnerExecutive officerMar 2017
Kevin G. PetersExecutive officerMar 2017
Stephen G. PakolaExecutive officerMar 2017
Anupam DalalDirectorMar 2025
Baiteng ZhaoDirectorMar 2025
Behzad AghazadehDirectorMar 2025
Caley CasteleinDirectorMar 2025
Dave LennonDirectorMar 2025
Emma ReeveDirectorMar 2025
Karin HehenbergerDirectorMar 2025
Mohammad HirmandDirectorMar 2025
Neil DesaiDirectorMar 2025
Richard MarounDirectorMar 2025
Karin HenebergerDirectorSep 2021
Anupam M. DalalDirectorMar 2017
Caley M. CasteleinDirectorMar 2017
Chau M. KhuongDirectorMar 2017
Joseph GardnerDirectorMar 2017
Muneer SatterDirectorMar 2017
Paul M. WeissDirectorMar 2017
Pravin M. DugelDirectorMar 2017
Steven M. PrelackDirectorMar 2017

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.